Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
about
Design and optimization of camptothecin conjugates of triple helix-forming oligonucleotides for sequence-specific DNA cleavage by topoisomerase I.Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sitesConversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff.Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivativesPhosphorylation of BLM, dissociation from topoisomerase IIIalpha, and colocalization with gamma-H2AX after topoisomerase I-induced replication damage.Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and Induces DNA strand break resealing.In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages.Topoisomerase assaysPoisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.Repair of topoisomerase I-mediated DNA damage.Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cellsInduction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells.Sequence selectivity of the cleavage sites induced by topoisomerase I inhibitors: a molecular dynamics study.Position- and orientation-specific enhancement of topoisomerase I cleavage complexes by triplex DNA structures.Enhancement of camptothecin-induced topoisomerase I cleavage complexes by the acetaldehyde adduct N2-ethyl-2'-deoxyguanosine.Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine.Induction of topoisomerase I cleavage complexes by the vinyl chloride adduct 1,N6-ethenoadenine.Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I.Distinct effects of topoisomerase I and RNA polymerase I inhibitors suggest a dual mechanism of nucleolar/nucleoplasmic partitioning of topoisomerase I.Cellular resistance to camptothecins.DNA sequence selectivity of human topoisomerase I-mediated DNA cleavage induced by camptothecin.Sequence-selective DNA cleavage by a topoisomerase I poison, NB-506.Antifungal actinomycete metabolites discovered in a differential cell-based screening using a recombinant TOPO1 deletion mutant strain.CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.DNA cleavage assay for the identification of topoisomerase I inhibitors.Gene homozygosis and mitotic recombination induced by camptothecin and irinotecan in Aspergillus nidulans diploid cells.Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4
P2860
Q31031515-E5FAC80C-E1B9-4C7C-A234-5E5061F463C1Q33932878-982250E4-71DD-41FD-9A35-0717F3E553C1Q33963811-447A6DCA-81AE-4EDF-A4A1-8DCCC00DC1CAQ34017703-A7EB5F9C-AE22-4BAA-B368-2B3514AED8DBQ34097292-F0543D7B-883D-497D-B77E-C1917C9015E3Q34286861-928549D6-4307-41A7-A73F-9A45C068291EQ34639985-B74D53E6-9045-48A5-87EC-BDBC1E298188Q35047219-A192801A-61B8-480B-BA44-20041ECC1751Q36096625-998FA36A-0451-4351-8362-CBB6E9E0E5DEQ36390575-647A2CA2-0685-4DEE-BC65-AF7FF13BD00DQ36557533-C6D4F99A-CEA5-4571-A093-0412562F3DE3Q36641418-9DFFB6DB-5C11-4E38-8C9C-E6F92DA7773DQ37061217-505BC697-0130-4D17-8C8D-F40F319DCE41Q37121596-65F48669-39FE-4131-AAED-E1B1C7B38A35Q37528750-06A8F07A-C665-46C0-84E4-0ECE10472071Q37564077-0AE77B6D-607D-480C-9557-E2D0FCF25399Q37592361-E69F92ED-CC76-47D7-8423-960CEF885149Q38326971-66D8CDE8-D19B-487E-BDF9-A29CA1CF1535Q38332699-27289DFA-79C4-4FC0-8A06-DCFDA878517AQ38347601-992D7472-028F-4CA7-A4FB-DA4EEFF16D3DQ40579913-86F884A4-4EB0-45CA-BF63-50FCC7798A58Q41307850-CAD2E524-9A4D-447E-A0A1-514807936A16Q42623345-276100DC-2516-4593-916A-5C65AA405EB9Q42670541-D150A942-F831-4D4D-99A5-4C55AB719DFAQ43645659-7CA9096A-0ABD-4646-9E12-3F5D59F3039AQ43827787-F6358E82-5A81-44B5-A9DE-3A6108E03CD1Q46312378-1EA504F9-A07A-46C3-8BC4-15A2262392EEQ52975439-B388379E-EDF9-4C79-868F-9CDF583C3902Q54982736-926F11F8-210D-4D60-8C69-624DED869AEAQ57810693-09E60CA5-D4F6-404E-AD10-36382549328D
P2860
Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Differential stabilization of ...... s by camptothecin derivatives.
@en
type
label
Differential stabilization of ...... s by camptothecin derivatives.
@en
prefLabel
Differential stabilization of ...... s by camptothecin derivatives.
@en
P2093
P356
P1433
P1476
Differential stabilization of ...... s by camptothecin derivatives.
@en
P2093
P304
P356
10.1021/BI00021A035
P407
P577
1995-05-01T00:00:00Z